gene_symbol
UNKNOWN
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
The vaccine primes neoantigen-specific T cells; CD4+ T cells recognize neoantigen–HLA class II on tumor cells and can lyse them via perforin/granzyme or Fas–FasL pathways (immune-mediated, not drug-delivered).
enzyme_product
Off
epitope
On
variant
On
isoform
Off
hla_specific
On
gated
Off
other_modifier
Presented via HLA-DR/HLA-DQ/HLA-DP to CD4+ T cells
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06195384
disease_id_num_tar_ref
2786
drug_id_num_tar_ref
7437